drugset
drugset / Trial / NCT07532148

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07532148 ↗

Phase 1 Not yet recruiting 24 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215

Timeline

Start
2026-06
Primary completion
2027-06
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-215 Unknown — —
Subject D215 Unknown — —

Indications

ovarian cancer